Idhifa (enasidenib) targets a specific gene mutation called IDH2, which can affect your bone marrow. IDH2 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in symptoms of acute myeloid leukemia.
Idhifa is used to treat acute myeloid leukemia in adults with an IDH2 mutation.
Idhifa is used when AML has come back or has not improved with prior treatment.
